TORONTO, ON — December 23, 2025 — Leads & Copy — Biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) has announced the appointment of Michael Kott to its board of directors, effective January 1, 2026. This follows the resignation of Paul Fornazzari from the board.
Kott brings over 35 years of experience in international capital markets, corporate finance, and fundraising to Avicanna. He is the Founder and CEO of CM-Equity AG, which he transitioned into a global single-family office focused on long-term value creation in 2025. Kott has a track record serving on public and private company boards, with expertise in governance, compliance, capital markets transactions, IPOs, and cross-border investments.
He is an active independent investor across public equities, venture capital, and alternative assets, with experience spanning biopharma and longevity, technology, cleantech, and sustainability.
Kott expressed his enthusiasm for joining Avicanna’s board, citing the company’s position in the “evidenced based natural pharmaceuticals megatrend” and its potential for significant impact. He also noted the recent communications from the White House regarding potential cannabis reclassification in the U.S. as a factor in his optimism about the company’s future. As a long-term shareholder, Kott stated his confidence in Avicanna’s management team and vision.
Aras Azadian, CEO of Avicanna Inc., thanked Fornazzari for his contributions to the board and welcomed Kott. Azadian believes Kott’s expertise related to capital markets will benefit the company as it aims to scale, expand, and unlock value for its shareholders.
Avicanna is focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. The company has a scientific platform including R&D and clinical development, leading to the commercialization of over thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.
These pillars include: the RHO Phyto™ medical cannabis formulary offering diverse products with varying cannabinoid ratios; the MyMedi.ca medical cannabis care platform operated by Northern Green Canada Inc.; a pharmaceutical pipeline of proprietary cannabinoid-based candidates in clinical development; and active pharmaceutical ingredients supplied by Santa Marta Golden Hemp SAS (SMGH), which provides CBD, THC, and CBG to international partners. SMGH also forms part of the company’s supply chain.
Ivana Maric, Avicanna Inc., info@avicanna.com
Source: Avicanna Inc.
